secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2024-03-18T23:59:59+00:00
Accession:  0001493152-24-010208
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi's FY2023 loss widens to $29.2M; cash only $1.9M; capital raise needed for key trials
--------------------------------------------------------------------------------

- Net loss for FY2023 was $29.2M ($1.73 per share) vs $25.4M ($2.99 per share) in FY2022.
- Cash and restricted cash totaled $2.1M at Dec 31, 2023, up from $0.6M a year prior but still low.
- Q4 R&D expenses rose to $4.0M (from $2.3M) and G&A to $5.9M (from $2.4M) year-over-year.
- City of Hope received $5.3M CIRM grant for CLD-101 ovarian cancer study; RTNova platform announced.
- Interim Phase 1 data for CLD-101 expected 2Q 2024 'assuming we are successful in raising additional capital.'

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000149315224010208/0001493152-24-010208-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000149315224010208/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-010208

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer